Why prosecuting Indian pharma patents could be even more difficult than it appears

A study released this month sheds new light on the Indian Patent Office’s (IPO’s) application of Section 3(d) of the country’s Patents Act – a controversial section intended to circumscribe the issue of ‘secondary’ rights for pharmaceuticals…